Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2025

Conditions
Prostate Cancer
Interventions
RADIATION

Hypofraction

Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).

RADIATION

Standard

Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists

Trial Locations (1)

G1R 2J6

CHUdeQuebec, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

CHU de Quebec-Universite Laval

OTHER